Yuefeng Mao

机构：Pingdingshan University, Xian Yang Central Hospital

发表论文 3 篇 · 总被引 38 次 · h-index 3

代表论文

• Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance (2022 · Frontiers in Pharmacology · 被引 18)
• Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer (2022 · Frontiers in Oncology · 被引 12)
• Anlotinib in recurrent or metastatic endometrial cancer (2022 · International Journal of Gynecological Cancer · 被引 8)